Separate ANDAs Are Required For Different Dosage Forms, FDA Guidance Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The draft guidance includes discussion of the Medicare Modernization Act's effect on FDA generic review processes, including application of 30-month stays and 180-day exclusivity. FDA will not amend its current definition of reference listed drugs, the guidance notes.